From a market perspective, I think the hype rise on the open to be expected and then the initial sell off, re-rise and stabilisation. The fact that even short term traders are hardly in the green and selling is bemusing to me. Perhaps shorter's see something I don't? Glad the results wern't worse?? Generally they look positive to me given the numbers of patients. There's a lot of good objective and subjective measures that give a good trend going forward. Don't underestimate that the EMA and FDA give more credence to patient testimony these days so WOMAC and use of pain medication will be important along with the MRI's and biomarkers. Safety issues limited to injection site only is very significant news for any drug application with the FDA. Yes there's a longish road ahead, but a partnership with MPS should be a good medium term catalyst for the SP (aka NEU you would hope). Feedback from the next talks with the EMA and FDA will be a good clue to hopefully a positive outcome. Where should the SP be ?? It's tough in the sector still but for the stage and the potential a great punt at these levels IMO. GLTA
- Forums
- ASX - By Stock
- PAR
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-48
-
- There are more pages in this discussion • 339 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M |
Open | High | Low | Value | Volume |
31.0¢ | 31.5¢ | 29.0¢ | $131.3K | 427.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 96541 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 7080 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 96541 | 0.290 |
4 | 47143 | 0.285 |
4 | 112550 | 0.280 |
3 | 43709 | 0.275 |
6 | 53106 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 7080 | 3 |
0.305 | 1272 | 2 |
0.310 | 64288 | 4 |
0.315 | 2457 | 1 |
0.320 | 53550 | 3 |
Last trade - 14.34pm 15/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online